TRANSLATE

The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

iwCLL 2017 | Progression on ibrutinib in patients with somatic mutations in the BCR and NF-kB pathways 

May 16, 2017


The second session at this year’s iwCLL was titled “Role of Non-Leukemic Cells and the Microenvironment in CLL Development”, and was jointly chaired by Silvia Deaglio (University of Turin, Torino, Italy) and Christopher Pepper (Cardiff University, Wales, UK).

A talk titled “Progression on ibrutinib in patients with somatic mutations in the BCR and NF-kB pathways” was given during this session by Clare Sun from the National Institutes of Health, Bethesda, Maryland.

The presentation began with a summary slide detailing resistance mechanisms to ibrutinib:

Following this, a phase II trial was outlined assessing ibrutinib in patients with CLL or SLL who require treatment and are older than 65 years, have del(17p), or have TP53 mutation (NCT01500733):

  • Overall, 84 patients enrolled
  • Ibrutinib 420mg one daily until disease progression or intolerable side effects
  • PFS at 36 months = 83.6%
  • Higher risk of progression found in patients with del(17p)/mutated TP53, Rai stage III/IV, and R/R CLL
  • Targeted sequencing found mutations in BTK and/or PLCG2 in 9/13 (69%) patients
  • Mutations identified up to 15.4 months before clinical progression, but not at treatment initiation

Clare Sun then asked two key questions: are there mutations in the BCR and NF-kB pathways at baseline? Can such mutations predict clinical outcome during ibrutinib treatment?

Upon whole exome sequencing of patients on ibrutinib monotherapy:

N (range or %)

 

Current study

Entire cohort

Patients

45

84

Age

66 (33–85)

67 (33–85)

Male

27 (60%)

49 (58%)

Rai stage III/IV

28 (62%)

59 (70%)

Del(17p)

25 (56%)

52 (62%)

Previously treated

19 (42%)

32 (38%)

In total, 23 somatic mutations in BCR and/or members of the NF-kB pathway were identified in 17 patients: 17 missense mutations (13 “damaging”; PolyPhen-2), 4 frameshift indels, and 2 splice site mutations.

Association with baseline features:

Prognostic factor

BCR and/or NF-kB pathway mutations

P value

No

Yes

Del(17p)/mutated TP53

67.9%

58.8%

0.7

U-IGHV

60.7%

58.8%

1.0

R/R CLL

35.7%

52.9%

0.4

Clare Sun then moved the talk on to discuss oncogenic CARD11 mutations in ABC-DLBCL, which is dependent on NF-kB activations via BCR and MYD88 signaling pathways. Ibrutinib results in better ORR in ABC- than GCB-DLBCL. However, no response occurred in ABC-DLBCL patients with mutations in TNFAIP3 or CARD11 (Wilson et al. 2015).

The presentation was concluded with a succinct summary slide:

References